posted on 2016-12-13, 10:01authored byCatherine John, María Soler Artigas, J. Hui, S. F. Nielsen, N. Rafaels, P. D. Paré, N. N. Hansel, Nick Shrine, I. Kilty, A. Malarstig, S. A. Jelinsky, S. Vedel-Krogh, K. Barnes, I. P. Hall, J. Beilby, A. W. Musk, B. G. Nordestgaard, A. James, Louise V. Wain, Martin D. Tobin
Background: Genome-wide association studies have identified numerous genetic regions that influence cross-sectional lung function. Longitudinal decline in lung function also includes a heritable component but the genetic determinants have yet to be defined.
Objectives: We aimed to determine whether regions associated with cross-sectional lung function were also associated with longitudinal decline and to seek novel variants which influence decline.
Methods: We analysed genome-wide data from 4167 individuals from the Busselton Health Study cohort, who had undergone spirometry (12 695 observations across eight time points). A mixed model was fitted and weighted risk scores were calculated for the joint effect of 26 known regions on baseline and longitudinal changes in FEV1 and FEV1/FVC. Potential additional regions of interest were identified and followed up in two independent cohorts.
Results: The 26 regions previously associated with cross-sectional lung function jointly showed a strong effect on baseline lung function (p=4.44×10−16 for FEV1/FVC) but no effect on longitudinal decline (p=0.160 for FEV1/FVC). This was replicated in an independent cohort. 39 additional regions of interest (48 variants) were identified; these associations were not replicated in two further cohorts.
Conclusions: Previously identified genetic variants jointly have a strong effect on cross-sectional lung function in adults but little or no effect on the rate of decline of lung function. It is possible that they influence COPD risk through lung development. Although no genetic variants have yet been associated with lung function decline at stringent genome-wide significance, longitudinal change in lung function is heritable suggesting that there is scope for future discoveries.
Funding
This work was supported by the Medical Research Council [G0902313 to MDT] and Pfizer. This
paper presents independent research funded partially by the National Institute for Health Research
(NIHR). The views expressed are those of the author(s) and not necessarily those of the NHS, the
NIHR or the Department of Health. This research used the ALICE and SPECTRE High Performance
Computing Facilities at the University of Leicester.
The Busselton Health Study acknowledges the support of the National Health and Medical Research
Council of Australia, the Government of Western Australia (Health Department, Sir Charles Gairdner
Hospital, PathWest and Healthway), Pfizer and the volunteers and participants of the study.
The Copenhagen City Heart Study was supported by Department of Clinical Biochemistry, Herlev and
Gentofte Hospital, Copenhagen University Hospital and the Danish Heart Foundation. We thank
staff and participants of the Copenhagen City Heart Study for their contribution.
The Lung Health Study (LHS) I was supported by the National Institutes of Health [contract NIH/N01-
HR-46002] and genome-wide association genotyping and analysis of LHS was supported by the
National Institutes of Health as part of the Gene Environment Association Studies (GENEVA)
[U01HG004738].
History
Citation
Thorax, 2017, 0:1-9.
Author affiliation
/Organisation/COLLEGE OF MEDICINE, BIOLOGICAL SCIENCES AND PSYCHOLOGY/School of Medicine/Department of Health Sciences
Version
VoR (Version of Record)
Published in
Thorax
Publisher
BMJ Publishing Group, British Thoracic Society (BTS)